ABS-106
/ Amberstone Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
Enhancing safety to unlock efficacy: A novel class of conditionally-activated T cell engagers for solid tumors
(AACR 2026)
- "ABS-106 exemplifies the precision-engineered, next-gen T-MATE™ TCE with optimal safety-efficacy balance. This smarter, safer TCE design enables potent anti-tumor efficacy while minimizing systemic toxicity, representing a promising therapeutic strategy for solid tumors and other indications."
Clinical • IO biomarker • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CD69 • CD8 • GZMB • PD-1 • STEAP1
1 to 1
Of
1
Go to page
1